Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors

View ORCID ProfileZishan Jiwani, View ORCID ProfileSimon B. Goldberg, View ORCID ProfileJack Stroud, Jacob Young, John Curtin, View ORCID ProfileJohn D. Dunne, View ORCID ProfileOtto Simonsson, View ORCID ProfileChristian A. Webb, Robin Carhart-Harris, View ORCID ProfileMarco Schlosser
doi: https://doi.org/10.1101/2024.08.27.24312677
Zishan Jiwani
1Department of Counseling Psychology, University of Wisconsin – Madison
2Center for Healthy Minds, University of Wisconsin – Madison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zishan Jiwani
Simon B. Goldberg
1Department of Counseling Psychology, University of Wisconsin – Madison
2Center for Healthy Minds, University of Wisconsin – Madison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Simon B. Goldberg
  • For correspondence: sbgoldberg{at}wisc.edu marco.schlosser{at}ucl.ac.uk
Jack Stroud
3Division of Psychology and Language Sciences, Faculty of Brain Sciences, University College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jack Stroud
Jacob Young
1Department of Counseling Psychology, University of Wisconsin – Madison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Curtin
2Center for Healthy Minds, University of Wisconsin – Madison
4Department of Psychology, University of Wisconsin – Madison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John D. Dunne
2Center for Healthy Minds, University of Wisconsin – Madison
5Department of Asian Languages and Cultures, University of Wisconsin – Madison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for John D. Dunne
Otto Simonsson
6Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Otto Simonsson
Christian A. Webb
7Department of Psyciatry, Harvard Medical School, Boston, MA, USA
8Center for Depression, Anxiety and Stress Research, McLean Hospital, Belmont, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christian A. Webb
Robin Carhart-Harris
9Department of Neurology, University of CA-San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Schlosser
10Division of Psychiatry, Faculty of Brain Sciences, University College London, London, United Kingdom
11Institut für Psychotherapie Potsdam, Potsdam, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marco Schlosser
  • For correspondence: sbgoldberg{at}wisc.edu marco.schlosser{at}ucl.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction Meditation practice and psychedelic use have attracted increasing attention in the public sphere and scientific research. Both methods induce non-ordinary states of consciousness that may have significant therapeutic benefits. Thus, there is growing scientific interest in potential synergies between psychedelic use and meditation practice with some research suggesting that psychedelics may benefit meditation practice. The present study examined individual, psychedelic-related, and meditation-related factors to determine under what conditions meditators perceive psychedelic use as beneficial for their meditation practice.

Method Participants (N = 863) who had reported psychedelic use and a regular meditation practice (at least 3 times per week during the last 12 months) were included in the study. To accommodate a large number of variables, machine learning (i.e., elastic net, random forest) was used to analyze the data.

Results Most participants (n = 634, 73.5%) found psychedelic use to have a positive influence on their quality of meditation. Twenty-eight variables showed significant zero-order associations with perceived benefits even following a correction. Elastic net had the best performance (R2 = .266) and was used to identify the most important features. Across 53 variables, the model found that greater use of psychedelics, intention setting during psychedelic use, agreeableness, and exposure to N,N-Dimethyltryptamine (N,N-DMT) were most likely to be associated with the perception that psychedelics benefit meditation practice. The results were consistent across several different approaches used to identify the most important variables (i.e., Shapley values, feature ablation).

Discussion Results suggest that most meditators found psychedelic use to have a positive influence on their meditation practice, with: 1) regularity of psychedelic use, 2) the setting of intentions for psychedelic use, 3) having an agreeable personality, and 4) reported use of N,N-DMT being the most likely predictors of perceiving psychedelic use as beneficial. Longitudinal designs and randomized trials manipulating psychedelic use are needed to establish causality.

Competing Interest Statement

OS was a co-founder of Eudelics AB and has once received a small payment from Mindfully Sweden AB for educational content. CAW has received consulting fees from King & Spalding law firm.

Funding Statement

The author(s) received no specific funding for this work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study received ethical approval from University College London (Project ID: 10043/004) and was performed in accordance with the 1964 Declaration of Helsinki and its later amendments.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data, R code, study items and consent form used in the study are available at the Open Science Framework (https://osf.io/56utj/?view_only=fb526198b6e3492ab90d5a7baffa9ca6)

https://osf.io/56utj/?view_only=fb526198b6e3492ab90d5a7baffa9ca6

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted August 28, 2024.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors
Zishan Jiwani, Simon B. Goldberg, Jack Stroud, Jacob Young, John Curtin, John D. Dunne, Otto Simonsson, Christian A. Webb, Robin Carhart-Harris, Marco Schlosser
medRxiv 2024.08.27.24312677; doi: https://doi.org/10.1101/2024.08.27.24312677
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors
Zishan Jiwani, Simon B. Goldberg, Jack Stroud, Jacob Young, John Curtin, John D. Dunne, Otto Simonsson, Christian A. Webb, Robin Carhart-Harris, Marco Schlosser
medRxiv 2024.08.27.24312677; doi: https://doi.org/10.1101/2024.08.27.24312677

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)